All Access

Pro Rata Premium

Axios Pro Rata Premium

Standard

Axios Pro Rata: Non-Premium Subscribers

Other

The week that was

Other deals of the week

Pipeline picks

Quote of the week

💰 Nordic-backed ArisGlobal on a deal search

ArisGlobal appears to be trying to address the SaaSpocalypse by building out its agentic platform.

💊 AbbVie strikes $10.9B deal for Apogee Therapeutics

The deal gives AbbVie a credible challenger to Sanofi's blockbuster Dupixent in atopic dermatitis.

👀 Nura Bio raises nearly $74M to advance SARM1 drugs in ALS

The funding comes as SARM1 draws growing attention as a potential target for neurodegenerative diseases.

Nordic-backed ArisGlobal on a deal search

AbbVie strikes $10.9B deal for Apogee Therapeutics

Nura Bio raises nearly $74M to advance SARM1 drugs in ALS

1 big thing: The week that was

Illustration of a syringe casting a shadow shaped like a question mark.

• Ollin Biosciences, an Austin, Texas-based ophthalmology biotech, raised $330m in Series B funding. TCGX and Arch Venture Partners led, joined by a16z, Blackstone, Commodore Capital, RA Capital Management, and CPPIB. axios.link/4xNogcC

• Osanni Bio, an SF-based biotech whose lead candidate focuses on dry age-related macular degeneration, raised $190m in Series B funding. Patient Square Capital led, joined by Horowitz Group, Invus Opportunities and the Retinal Degeneration Fund. axios.link/4eKSep7

• Bionyra Pharma, a biotech focused on immune-mediated inflammatory diseases, raised $165m in Series A funding. Jeito Capital and Sofinnova Partners led, joined by Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners and Apollo Health Ventures. axios.link/3QZmrsF

• RQ Bio, a London-based developer of long-acting antivirals for influenza, raised £85.5m in Series A funding. Frazier Life Sciences led, joined by EQT Life Sciences, Forbion, Monograph, Wellington Management, and LifeArc Ventures. axios.link/3St724i

• Lycia Therapeutics, a biotech targeting disease-causing extracellular proteins, raised $75m in Series D funding. Balyasny Asset Management led, joined by Adage Capital Management, HBM Healthcare Investments, OrbiMed, Eli Lilly, Franklin Templeton, Invus, RTW Investments and Venrock Healthcare Capital Partners. axios.link/4xQybhQ

• Oblenio Bio, a Cambridge, Mass.-based biotech focused on autoimmune disease, raised $62m in Series B funding. Pfizer Ventures led, joined by Deep Track Capital, GV, and Aditum Bio. axios.link/4vFrVrF

• Trimtech Therapeutics, a U.K. biotech focused on neurodegenerative diseases, raised $14m in seed extension funding led by Johnson & Johnson Innovation. axios.link/4uMZo21

• ChemT, a Singapore-based startup focused on AI biomanufacturing, raised $4m in seed funding led by Wavemaker Ventures and Seeds. Wavemaker 360 Health, Draper University Ventures, and Temasek Life Sciences Accelerator joined. axios.link/4agHBsL

• Stada, a German drugmaker owned by CapVest, is weighing a €6b takeover of Cooper Consumer Health, a Dutch personal care products maker owned by CVC Capital Partners, per Bloomberg. axios.link/3Slv9lu

• Agilent Technologies (NYSE: A) completed its $950m acquisition of Biocare Medical, a Pacheco, Calif.-based maker of cancer research tools and materials, from Excellere Partners and GHO Capital. axios.link/4bbXqR5

• Remix Therapeutics, a Watertown, Mass.-based RNA processing reprogramming biotech, is going public via a reverse merger with Passage Bio (Nasdaq: PASG). Remix has raised over $200m from firms like Arch Venture Partners, Column Group, WTT Investment, Willett Advisors, Atlas Venture, Foresite Capital, Alexandria Venture Investments, Casdin Capital, and Surveyor Capital. axios.link/4v2gN74

• Merck of Germany agreed to buy Bio-Techne (Nasdaq: TECH), a Minneapolis-based lab tools maker, for $11.4b in cash, or $73 per share (24% premium to yesterday's closing price). axios.link/44yu1gU

• Novartis (NYSE: NVS) will pay Antares Therapeutics (Nasdaq: ATRS) $105m upfront and up to $1.8b in additional payments to develop new cancer treatments. Go deeper

• Eli Lilly (NYSE: LLY) will pay up to $1.9b to Abbisko Therapeutics, a cancer-focused Chinese biotech, to develop new drug candidates. Go deeper

2. Other deals of the week

Illustration of pills arranged in a crescent moon phase pattern.

👥 Finalists emerge to lead FDA — Axios

🚪 Moderna enters in vivo CAR-T — Fierce Biotech 

🗯️ Medical breakthroughs collide with the health system — Axios

💉 FDA gives third rare-disease drug another shot, Regenxbio says — WSJ

🤝 How GSK's new CEO lined up a major buyout to start his time  — Endpoints

3. Pipeline picks

Illustration of a dollar sign and asterisk on a prescription bottle magnified by a magnifying glass.

"I would say these recent events ... have really been a breath of fresh air. These are dramatic, positive developments. It really discards the previous regime's, I would say, unhealthy fixation on methodological purity."

— Tim Hunt, CEO of the Alliance for Regenerative Medicine, on recent industry-friendly FDA decisions

4. Quote of the week

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

transportation

business

c-suite

retail-news

June 27, 2026

1 big thing: The week that was